Related Experiment Video
Updated: Dec 29, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
Nucleic Acid-Based Therapies for Atherosclerosis.
Petri Mäkinen1, Anna-Kaisa Ruotsalainen1, Seppo Ylä-Herttuala2,3
1A.I. Virtanen Institute, University of Eastern Finland, Neulaniementie 2, P.O. Box 1627, 70211, Kuopio, Finland.
Novel RNA-based therapies, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), show promise for treating atherosclerosis by targeting lipid and lipoprotein metabolism. Further clinical studies are needed to confirm their efficacy in larger patient populations.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Pharmacology
Background:
- Atherosclerosis involves lipid accumulation and inflammation in arteries.
- Current treatments focus on managing atherosclerosis risk factors.
Purpose of the Study:
- To review nucleic acid-based therapeutics for atherosclerosis.
- To introduce novel RNA molecules with therapeutic potential.
Main Methods:
- Review of clinical trials and preclinical studies.
- Focus on antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs).
Main Results:
- RNA-based inhibitors targeting PCSK9, Lp(a), ApoCIII, and ANGPTL3 show success in clinical trials.
- MicroRNAs and long non-coding RNAs demonstrate atherogenesis reduction in preclinical models.
- Liver-directed ASOs and siRNAs targeting lipid metabolism yield promising clinical results.
Conclusions:
- Nucleic acid-based therapies, particularly ASOs and siRNAs, offer a promising new avenue for atherosclerosis treatment.
- Further research in larger patient cohorts is essential to fully establish the therapeutic potential of these RNA-based drugs.
More Related Videos
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Related Concept Videos
Atherosclerosis III: Management
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Atherosclerosis I: Introduction
Atherosclerosis IV: Nursing Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Lipid-Lowering Drugs: Statins and Miscellaneous Agents